Christine M. Eischen

8.9k citations

99 papers · 6.8k indexed · 2 hit papers · h-index 44

Impact in

Oncology top 0.5%
- Cancer-related Molecular Pathways
Cancer Research top 1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research

Papers in

Oncology 44
- Cancer-related Molecular Pathways 37
Cancer Research 23
- Cancer-related molecular mechanisms research 16
- MicroRNA in disease regulation 12

Co-authors: John L. Cleveland Martine F. Roussel Charles J. Sherr Paul J. Leibson Clare M. Adams Takehiko Kamijo Frédérique Zindy David H. Randle
Journals: Oncogene (14 papers)Cancer Research (8 papers)Blood (5 papers)Molecular Cancer Research (4 papers)The Journal of Immunology (4 papers)
Partner nations: United States France China

In The Last Decade

Christine M. Eischen

98 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis 1999 · 667 citations

Peers

Countries citing papers authored by Christine M. Eischen

Since Specialization

Citations

This map shows the geographic impact of Christine M. Eischen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine M. Eischen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine M. Eischen more than expected).

Fields of papers citing papers by Christine M. Eischen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine M. Eischen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine M. Eischen. The network helps show where Christine M. Eischen may publish in the future.

Co-authors

The 25 scholars most cited alongside Christine M. Eischen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christine M. Eischen Line = papers co-authored together Christine M. Eischen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells Blood Advances ·Michael Lawler, Jennifer S. Romer-Seibert, Michael Bowman, Ramkrishna Mitra, Christine M. Eischen, Robert L. Bowman, Sara E. Meyer	2025	0
2	Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer Cancer Discovery ·Clare M. Adams, Ramkrishna Mitra, You‐Cai Xiao, Peter Michener, Juan Palazzo, Allen Chao, Jitendra Gour, Joel Cassel, Joseph M. Salvino, Christine M. Eischen	2023	57
3	MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1 eLife ·Tessa M. Popay, Jing Wang, Clare M. Adams, Gregory C. Howard, Simona G. Codreanu, Stacy D. Sherrod, John A. McLean, Lance R. Thomas, Shelly L. Lorey, Yuichi Machida, April M. Weissmiller, Christine M. Eischen, Qi Liu, William P. Tansey	2021	58
4	Smarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress Cancer Research ·Matthew V. Puccetti, Clare M. Adams, Saul Kushinsky, Christine M. Eischen	2019	27
5	Targeting of SGK1 by miR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion Molecular Cancer Research ·Evan J. Greenawalt, Mick D. Edmonds, Neha Jain, Clare M. Adams, Ramkrishna Mitra, Christine M. Eischen	2018	36
6	Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells Cancer Research ·Kyle P. Feeley, Clare M. Adams, Ramkrishna Mitra, Christine M. Eischen	2017	42
7	Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW Clinical Cancer Research ·Clare M. Adams, Ramkrishna Mitra, Jerald Z. Gong, Christine M. Eischen	2017	24
8	The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development Molecular Cancer Therapeutics ·Shuang Liu, Ramkrishna Mitra, Mingming Zhao, Wenhong Fan, Christine M. Eischen, Feng Yin, Zhongming Zhao	2016	53
9	Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution Oncogene ·Matthew V. Puccetti, Melissa A. Fischer, Maria P. Arrate, Kelly L. Boyd, Robert J. Duszynski, Rémy Betous, David Cortez, Christine M. Eischen	2016	13
10	Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells Molecular Cancer Research ·Alexia M. Carrillo, Mellissa Hicks, Dineo Khabele, Christine M. Eischen	2015	24
11	Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies Cancer Research ·Clare M. Adams, Scott W. Hiebert, Christine M. Eischen	2015	43
12	Oncogenic Protein MTBP Interacts with MYC to Promote Tumorigenesis Cancer Research ·Brian C. Grieb, Mark Gramling, Maria P. Arrate, Xi Chen, Stephen L. Beauparlant, Dale S. Haines, Hua Xiao, Christine M. Eischen	2014	34
13	Cell survival is dicey without Dicer Molecular & Cellular Oncology ·Clare M. Adams, Christine M. Eischen	2014	4
14	Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer RNA ·Ramkrishna Mitra, Mick D. Edmonds, Jingchun Sun, Min Zhao, Hui Yu, Christine M. Eischen, Zhongming Zhao	2014	44
15	RABL6A, a Novel RAB-Like Protein, Controls Centrosome Amplification and Chromosome Instability in Primary Fibroblasts PLoS ONE ·Xuefeng Zhang, Jussara Hagen, Viviane P. Muniz, Tarik Smith, Gary S. Coombs, Christine M. Eischen, Duncan I. Mackie, David L. Roman, Richard Van Rheeden, Benjamin W. Darbro, Van S. Tompkins, Dawn E. Quelle	2013	10
16	Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis Cell Death and Differentiation ·Mark Gramling, Christine M. Eischen	2012	31
17	p53 and MDM2: Antagonists or Partners in Crime? Cancer Cell ·Christine M. Eischen, Guillermina Lozano	2009	37
18	The ARF Tumor Suppressor Can Promote the Progression of Some Tumors Cancer Research ·Olivier Humbey, Julia Pimkina, Jack T. Zilfou, Michal Jarník, Carmen Dominguez‐Brauer, Darren J. Burgess, Christine M. Eischen, Maureen E. Murphy	2008	43
19	Decreased Mdm2 expression inhibits tumor development induced by loss of ARF Oncogene ·P Wang, Timothy C. Greiner, Tamara Lushnikova, Christine M. Eischen	2006	24
20	The Fas Pathway in Apoptosis Advances in pharmacology ·Christine M. Eischen, Paul J. Leibson	1997	24

About Christine M. Eischen

Christine M. Eischen is a scholar working on Oncology, Cancer Research, Molecular Biology, Immunology and Biotechnology, having authored 99 papers that have together received 6.8k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (37 papers), Cell death mechanisms and regulation (20 papers), DNA Repair Mechanisms (19 papers), Cancer-related molecular mechanisms research (16 papers), Epigenetics and DNA Methylation (15 papers), RNA modifications and cancer (14 papers), Ubiquitin and proteasome pathways (14 papers) and MicroRNA in disease regulation (12 papers). The work is most often cited by research in Oncology (3.1k citations), Cancer Research (1.5k citations), Molecular Biology (5.0k citations), Immunology (1.1k citations) and Biotechnology (324 citations). Christine M. Eischen has collaborated with scholars based in United States, France and China. Frequent co-authors include John L. Cleveland, Martine F. Roussel, Charles J. Sherr, Paul J. Leibson, Clare M. Adams, Takehiko Kamijo, Frédérique Zindy, David H. Randle, Jason D. Weber and Ramkrishna Mitra. Their work appears in journals such as Oncogene, Cancer Research, Blood, Molecular Cancer Research and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact